New Drug Selinexor (Xpovio) Has Many Risks, Limited Benefits Against Non-Hodgkin Lymphoma

Fact Checked

SurvivorNet Fact Checking and Medical Review Standards:  

The SurvivorNet News Team creates high quality medical information that complies with our industry leading standards for factual accuracy and sourcing from leading experts at academic medical institutions. Every news article is thoroughly fact-checked by our physician collaborators. We vet each piece of work for factual integrity, impartiality, and clearly label any professional conflicts.

All SurvivorNet articles adhere to the following standards:

  1. All studies and research papers cited are from reputable academic medical institutions or peer-reviewed journals.
  2. When we use data, statistics, or quotes these references link to the original source.
  3. All content related to new treatments, drugs, procedures, and so on must clearly describe availability, side effects, treatment target (such as triple negative breast cancer)
  4. All medical information on SurvivorNet is sourced from respected medical professionals with verified medical credentials and links are provided to these sources.
  5. We strive to give the reader relevant background information and include, clearly-sourced contextual health information in all articles. Readers are clearly alerted to any conflicts of interest from a medical source or the authors of a cited study.
/ Updated November 16th, 2020

New Drug Selinexor (Xpovio) Has Many Risks, Limited Benefits Against Non-Hodgkin Lymphoma

×
NOW
PLAYING
Cancer Patients Should Still Wear Masks & Distance Says Leading Expert - Even in Wake of Major New CDC Guidelines
NOW
PLAYING
CRS: A CAR T-cell therapy side effect
NOW
PLAYING
New Hope For Stomach Cancer: Immunotherapy Drug Opdivo Now Approved As a First Treatment
NOW
PLAYING
All About Acute Lymphoblastic Leukemia
NOW
PLAYING
Some Hand Sanitizers Found to Contain Cancer-Causing Compound Benzene; How Cancer Patients Can Protect Themselves During COVID-19
NOW
PLAYING
Some Melanoma Survivors See Long-Term Side Effects After Immunotherapy, Says New Study

Recurrence: Options After Diffuse Large B-Cell Lymphoma Recurrence

SEE MORE   

Recurrence: Options After Diffuse Large B-Cell Lymphoma Recurrence

  • There are several treatment options available if non-Hodgkin lymphoma returns
  • The most common first treatment after relapse is another round of chemotherapy
  • For patients whose cancer does not respond well to chemo, doctors may explore immune-therapies such as CAR-T therapy
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.